EBMT Hot Review | Professor Depei Wu: PT-Cy Regimen for GVHD Prevention May Lead to T-Cell Diversity Deficiency, Significantly Impacting Efficacy and Safety

EBMT Hot Review | Professor Depei Wu: PT-Cy Regimen for GVHD Prevention May Lead to T-Cell Diversity Deficiency, Significantly Impacting Efficacy and Safety

2024.04.25
Graft-versus-host disease (GVHD) is one of the major complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT), exhibiting diverse clinical manifestations with prolonged course. Improper diagnosis and treatment can not only affect patients' quality of life but also have a significant impact on long-term survival. With the continuous improvement of modern transplant technology, patients' demand for post-transplant quality of life is increasing, emphasizing the importance of GVHD prevention and treatment. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT2024) was held in Glasgow, UK. On the second day of the conference, Leslie Kean and colleagues from the Dana-Farber/Boston Children's Cancer and Blood Disorders Center in the United States orally presented a clinical study (Abstract No. GS02-02), suggesting that the post-transplant cyclophosphamide (PT-Cy) regimen, while effectively controlling unrelated donor GVHD, may increase the risk of grade 2 or higher infections. Through further large-scale T-cell receptor (TCR) sequencing (TCR-seq), researchers found that PT-Cy significantly reduces patients' TCR diversity, which may be a contributing factor to the higher incidence of infections. We are pleased to invite Professor Depei Wu from The First Affiliated Hospital of Soochow University to provide insightful commentary on this study.
EBMT China’s Voice | Professor Hui Wang’s Team: Significance of Cytokines and T Cell Subsets in the Process of CD7 CAR-T Therapy

EBMT China’s Voice | Professor Hui Wang’s Team: Significance of Cytokines and T Cell Subsets in the Process of CD7 CAR-T Therapy

2024.04.25
From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, United Kingdom. The conference focused on the latest advances in stem cell transplantation and cell therapy, driving towards better clinical outcomes for patients with hematologic diseases and blood tumors. At this year's conference, a study by Professor Hui Wang's team from Beijing Lu Daopei Hematology Research Institute was included for poster presentation, revealing the significance of cytokines and T cell subsets in the process of CD7 CAR-T therapy. This journal invited Professor Hui Wang to share the research findings and their clinical significance with colleagues.
EBMT China’s Voice | Professors Ke Xiaoyan and Hu Kai’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy

EBMT China’s Voice | Professors Ke Xiaoyan and Hu Kai’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy

2024.04.25
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Ke Xiaoyan from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Hu Kai from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.